GET DAILY SIGNALSInnate Pharma (IPHA) Falls -12.9% Over 30 Days: Pipeline Timing and Next Catalysts
Key Takeaways
- Innate Pharma (IPHA) shares declined roughly 12.9% over the trailing 30 days, from a $1.70 close on September 28, 2026 to $1.48 on October 27, 2026.
- The pullback extended a fade from an early-August spike that followed the Sobi licensing agreement for lacutamab.
- A key near-term negative arrived when partner AstraZeneca (AZN) delayed the PACIFIC-9 Phase 3 monalizumab readout to the first half of 2027, from the second half of 2026.
- An important upcoming catalyst is initial Phase 1 dose-escalation data for the Nectin-4 antibody-drug conjugate IPH4502 at the EORTC-NCI-AACR conference on November 18, 2026.
- The company's cash runway was extended to early first-quarter 2028 following the Sobi upfront payment and a €30 million equity financing.
- Explore additional detail on valuation, results, and projections through the Price Targets, Earnings, and Forecast pages.
- See how automated strategies are positioning across thousands of tickers with Trending AI Robots.
Company Background and Market Position
Innate Pharma S.A. is a global, clinical-stage biotechnology company headquartered in Marseille, France, and dual-listed on Euronext Paris (IPH) and Nasdaq (IPHA). The company develops next-generation antibody immunotherapies for cancer, built on expertise in antibody engineering and target identification in immuno-oncology. Its proprietary pipeline centers on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AZN for non-small cell lung cancer (NSCLC). The company has established collaborations with leading biopharmaceutical partners including Sobi, Sanofi, and AZN. Investors follow IPHA primarily for clinical data catalysts and milestone-driven partnership economics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. the Quarter
Over the last 30 days, IPHA declined from a closing price of $1.70 on September 28, 2026 to $1.48 on October 27, 2026, a drop of about 12.9%. The move was largely a steady grind lower, with only modest intraday rebounds, and trading volumes remained relatively thin through most of the period. The quarterly picture tells a more volatile story. Shares began the period near $1.80 in late July 2026, then surged in early-to-mid August, briefly climbing above $2.50 on the announcement of the Sobi lacutamab licensing agreement. Those gains progressively faded through September and October, leaving the stock around 18% lower over roughly three months despite the August spike.
Drivers Behind the Recent 30-Day Decline
The dominant dynamic over the past month has been the unwinding of the enthusiasm that followed the August Sobi deal. As the initial catalyst passed and no immediate clinical readouts materialized, momentum and speculative interest cooled, contributing to a steady decline from the early-September range above $2.00 toward the mid-$1.40s. A specific negative arrived in late October, when Innate announced that AZN had updated the expected timing for the PACIFIC-9 Phase 3 trial readout to the first half of 2027, from the second half of 2026 previously. The revision reflects the event-driven nature of the study, but it removes a near-term data catalyst for the monalizumab program and weighed on sentiment. Broader pressure on small-cap and pre-revenue biotech names, combined with the stock's modest liquidity, also amplified the downward move.
Quarterly Performance and Key Developments
The quarter's defining event was the August announcement of a strategic partnership granting Sobi global rights to lacutamab in T-cell lymphomas. The agreement included a $75 million upfront payment, up to $40 million in near-term Sézary syndrome-related milestones, and up to $465 million in additional milestones, plus tiered double-digit royalties. Innate also completed a €30 million equity financing, and the company said these moves extended its expected cash runway to the end of the first quarter of 2028. Beyond the financing news, the company progressed its clinical pipeline: enrollment in the IPH4502 Phase 1 dose-escalation and cohort enrichment was completed with preliminary antitumor activity observed, and the TELLOMAK-3 confirmatory Phase 3 study for lacutamab was initiated. However, the delayed PACIFIC-9 readout and the absence of near-term data releases allowed the post-announcement rally to reverse, shaping the stock's net-negative quarterly performance.
Key Drivers for the IPHA Outlook
Several clinical and financial milestones will shape IPHA's outlook. The nearest is the presentation of initial Phase 1 dose-escalation data for IPH4502 at the EORTC-NCI-AACR conference on November 18, 2026, which could clarify the ADC's activity and safety profile. Looking further ahead, Innate plans first-patient enrollment in the TELLOMAK-3 Phase 3 study in the first quarter of 2027 and an accelerated approval submission for lacutamab in Sézary syndrome in the second half of 2027. The PACIFIC-9 monalizumab readout is now expected in the first half of 2027. Investors should also monitor the company's cash position and any additional non-dilutive financing or partnership activity, given the costs of advancing late-stage programs. Macro conditions for pre-revenue biotech companies, competitive developments in the ADC and T-cell lymphoma spaces, and analyst expectations around data timing will all influence sentiment. As always, clinical outcomes carry meaningful binary risk.
Reviewing Automated Strategies in Biotech
In my research process, I often review Tickeron’s Trending AI Robots to understand how algorithmic approaches are positioned across the broader market, including names like IPHA. This offers a neutral perspective on strategy performance without relying on any single system.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IPHA's RSI Indicator climbs out of oversold territory
The RSI Oscillator for IPHA moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 78 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +10.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IPHA as a result. In 90 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.081) is normal, around the industry mean (3.037). P/E Ratio (-2.902) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment
Industry Biotechnology
Advertisement